☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC July Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Vildagliptin in combination with metformin (Eucreas®) has been accepted for restricted use (PDF). The combination should be used in patients for whom monotherapy with metformin provides insufficient glycaemic control and where the addition of a sulphonylurea is not appropriate. In this instance the addition of vildagliptin is an alternative to using glitazones.

Fesoterodine fumarate (Toviaz®) has also been accepted for restricted use (PDF). The advice notes that this drug is equivalent to existing therapies in terms of efficacy and also has a typical adverse event profile. The higher acquisition cost restricts this new drug to second-line use.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC July Update' by emailShare 'SMC July Update' on FacebookShare 'SMC July Update' on TwitterShare 'SMC July Update' on LinkedInShare 'SMC July Update' on reddit


No Comments to “SMC July Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.